During the past decade, Sahyadri Specialty Hospital conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 10 clinical trials were completed, i.e. on average, 55.6% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 7 clinical trials were completed. i.e. 70% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sahyadri Specialty Hospital" #1 sponsor was "Pfizer" with 11 trials, followed by "Octapharma" with 2 trials sponsored, "Astellas Pharma Inc" with 1 trials sponsored, "Baxalta now part of Shire" with 1 trials sponsored and "Geron Corporation" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sahyadri Specialty Hospital" #1 collaborator was "Instituto Grifols, S.A." with 2 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "Basilea Pharmaceutica International Ltd" with 1 trials as a collaborator, "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator and "Biomedical Advanced Research and Development Authority" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Sahyadri Specialty Hospital" are "Hemophilia A" (3 trials), "Hemophilia B" (3 trials), "Congenital Afibrinogenemia" (2 trials), "ACUTE LYMPHOBLASTIC LEUKEMIA" (1 trials) and "Advanced Non-Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Sahyadri Specialty Hospital" in a lesser frequency.

Most popular intervention types in "Sahyadri Specialty Hospital" are "Drug" (15 trials), "Biological" (7 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Lorlatinib" (2 trials), "PF-06741086" (2 trials), "Placebo" (2 trials), "ATM-AVI" (1 trials) and "Avelumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Sahyadri Specialty Hospital" are 17 trials for "All" genders, 4 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Sahyadri Specialty Hospital". undefined are not yet recruiting, 4 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Sahyadri Specialty Hospital, 1 suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Sahyadri Specialty Hospital, 2 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 0 trials that are defined as “Not Applicable".